Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Chemed Analyst Ratings and Price Targets | NYSE:CHE | Benzinga
Chemed Corp has a consensus price target of $662 based on the ratings of 2 analysts. The high is $674 issued by RBC Capital on April 28, 2025. The low is $650 issued by Oppenheimer on February 29, 2024. The 3 most-recent analyst ratings were released by RBC Capital on April 28, 2025, March 14, 2025, and November 5, 2024, respectively. With an average price target of $658 between RBC Capital, there's an implied 14.33% upside for Chemed Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Chemed
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/28/2025 | Buy Now | 17.11% | RBC Capital | Ben Hendrix60% | $667 → $674 | Maintains | Outperform | Get Alert |
| 03/14/2025 | Buy Now | 15.9% | RBC Capital | Ben Hendrix60% | $633 → $667 | Maintains | Outperform | Get Alert |
| 11/05/2024 | Buy Now | 9.99% | RBC Capital | Ben Hendrix60% | $697 → $633 | Maintains | Outperform | Get Alert |
| 05/21/2024 | Buy Now | 21.11% | RBC Capital | Ben Hendrix60% | $712 → $697 | Maintains | Outperform | Get Alert |
| 03/04/2024 | Buy Now | 23.72% | RBC Capital | Ben Hendrix60% | $604 → $712 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | 12.94% | Oppenheimer | Michael Wiederhorn61% | $625 → $650 | Maintains | Outperform | Get Alert |
| 01/17/2024 | Buy Now | 8.6% | Oppenheimer | Michael Wiederhorn61% | $590 → $625 | Maintains | Outperform | Get Alert |
| 10/30/2023 | Buy Now | 4.95% | RBC Capital | Ben Hendrix60% | $576 → $604 | Maintains | Outperform | Get Alert |
| 07/31/2023 | Buy Now | 0.08% | RBC Capital | Ben Hendrix60% | $610 → $576 | Maintains | Outperform | Get Alert |
| 07/27/2023 | Buy Now | 2.52% | Oppenheimer | Michael Wiederhorn61% | $610 → $590 | Maintains | Outperform | Get Alert |
| 05/01/2023 | Buy Now | 5.99% | RBC Capital | Ben Hendrix60% | $587 → $610 | Maintains | Outperform | Get Alert |
| 04/28/2023 | Buy Now | 5.99% | Oppenheimer | Michael Wiederhorn61% | $580 → $610 | Maintains | Outperform | Get Alert |
| 02/27/2023 | Buy Now | 2% | RBC Capital | Ben Hendrix60% | $545 → $587 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | -5.3% | RBC Capital | Ben Hendrix60% | $541 → $545 | Maintains | Outperform | Get Alert |
| 08/01/2022 | Buy Now | -6% | RBC Capital | Ben Hendrix60% | $592 → $541 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Chemed (CHE) stock?
The latest price target for Chemed (NYSE:CHE) was reported by RBC Capital on April 28, 2025. The analyst firm set a price target for $674.00 expecting CHE to rise to within 12 months (a possible 17.11% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Chemed (CHE)?
The latest analyst rating for Chemed (NYSE:CHE) was provided by RBC Capital, and Chemed maintained their outperform rating.
When was the last upgrade for Chemed (CHE)?
There is no last upgrade for Chemed
When was the last downgrade for Chemed (CHE)?
There is no last downgrade for Chemed.
When is the next analyst rating going to be posted or updated for Chemed (CHE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemed was filed on April 28, 2025 so you should expect the next rating to be made available sometime around April 28, 2026.
Is the Analyst Rating Chemed (CHE) correct?
While ratings are subjective and will change, the latest Chemed (CHE) rating was a maintained with a price target of $667.00 to $674.00. The current price Chemed (CHE) is trading at is $575.52, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
